What did @drteresawood actually say?
Dr. Wood celebrated British Columbia's announcement that menopause hormone medications will be covered provincially, framing it as a corrective to decades of undertreated women's health. She argued the 2001 Women's Health Initiative scared clinicians away from hormone therapy through misinterpretation, and that the resulting 75% drop in prescribing led to measurably earlier deaths and illness in women. She also claimed antidepressants are "second line" for menopause symptoms, and that estrogen, progesterone, or testosterone would have solved problems that women are instead being prescribed multiple drugs for in their 40s and 50s.
She also mentioned belonging to the International Society for the Study of Women's Sexual Health (ISSWSH), a real and credible organization, and flagged a physician menopause mentorship program she's enrolled in. The tone is advocacy-first, which is fine, but advocacy and accuracy aren't always the same thing.
Does the science back this up?
More than you might expect, yes. The WHI misinterpretation critique is well-documented and legitimate. The claim about antidepressants being second line is consistent with current clinical guidance. The "earlier death" framing is supported but requires more precision than she offered.
The 2002 WHI publication (Rossouw et al., JAMA 2002) triggered a widespread pullback from hormone therapy. Subsequent re-analysis, particularly the "timing hypothesis" work by Manson et al. (NEJM 2016), showed that women who initiated HRT within 10 years of menopause had lower cardiovascular risk, not higher. A 2023 Menopause journal analysis (Baber et al.) confirmed that the blanket fear response to WHI led to a generation of under-treated women. The Nurses' Health Study cohort data also linked HRT discontinuation to increased all-cause mortality in certain age groups. So the "earlier death" framing is not invented, though the precise 75% figure for prescribing reduction is harder to pin to a single source, and she doesn't provide one.
What did they get wrong (or right)?
The 75% reduction in prescribing is a real phenomenon, but citing it as a causal driver of earlier death without a direct citation is a logical leap the evidence doesn't fully support yet. It's plausible. It's not proven. She presents it as settled fact.
Her claim that antidepressants "don't treat the focus" and "don't treat the palpitations" is broadly correct. SSRIs and SNRIs are approved for vasomotor symptoms but have no strong evidence for cognitive symptoms or palpitations in perimenopause. The Menopause Society (formerly NAMS) 2023 position statement lists hormone therapy as first-line for vasomotor symptoms in appropriate candidates, with antidepressants as alternatives for those who can't use hormones. So calling them "second line" is accurate in that context.
She gets real credit for flagging topical versus oral delivery differences. Oral estrogen increases clotting risk in a way transdermal does not, which Canonico et al. (Thrombosis and Haemostasis, 2010) demonstrated clearly. That's a clinically important distinction she mentioned correctly.
What she oversimplifies: not every woman in her 40s and 50s with mood, sleep, or weight issues needs hormones. She implies estrogen, progesterone, or testosterone "would probably have done the trick" for a broad range of conditions. That's advocacy outrunning evidence.
What should you actually know?
BC's coverage decision is real and significant. If you're in British Columbia, your province now covers hormone therapy for menopause, which removes a financial barrier that previously pushed many women toward under-treatment or no treatment at all. That's a genuine policy win.
The WHI rehabilitation story is legitimate science, not fringe revisionism. Multiple reanalyses have confirmed that age at initiation and years since menopause matter enormously for risk-benefit calculations. Hormone therapy is not the same risk for a 52-year-old newly menopausal woman as it is for a 70-year-old who hasn't used hormones in decades.
Testosterone for women is a real and under-discussed area. The ISSWSH and British Society for Sexual Medicine have published guidelines supporting testosterone for hypoactive sexual desire disorder in women, though it remains off-label in most countries. Dr. Wood's involvement with ISSWSH is relevant context here.
- If you're perimenopausal and being offered only antidepressants for hot flashes, sleep disruption, or cognitive symptoms, it is reasonable to ask your provider whether hormone therapy has been considered and why it was or wasn't recommended for you.
- Topical and transdermal hormone delivery carries different risk profiles than oral. This is worth asking about specifically.
- The BC coverage applies to provincially insured residents. Specific drugs covered, dosage forms, and eligibility criteria vary. Check BC PharmaCare directly.
Bottom line
Dr. Wood is largely telling a story the research supports, but she rounds some rough edges smooth. The WHI critique is valid. The antidepressant-as-second-line point is accurate. The mortality data is real but more nuanced than her framing. The implied promise that hormones would solve most of what ails women in their 40s and 50s is where she crosses from education into oversell. That doesn't make her wrong, it makes her an advocate, which is a different job than a clinician in an exam room weighing your individual risk profile.